Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Researchers evaluated leaf extracts from three Italian plants for activity against triple‑negative breast cancer (TNBC). Salvia pratensis showed the strongest selective effect, cutting viability of MDA‑MB‑231 cells by roughly one‑third while sparing non‑cancerous MCF‑10A cells. The extract triggered mitochondrial reactive oxygen species, G0/G1 cell‑cycle arrest, and apoptosis, accompanied by a four‑fold rise in tumor‑suppressive miR‑34a‑5p. These findings suggest Salvia pratensis as a promising source of bioactive compounds for TNBC therapy.
The review highlights Rehmannia glutinosa polysaccharides (RGPs) as multifunctional heteropolysaccharides with immunomodulatory, anti‑inflammatory, antitumor, anti‑aging, and metabolic benefits. It details how structural attributes—molecular weight, monosaccharide composition, and glycosidic linkages—drive these activities and why poor oral bioavailability and batch variability impede...
Voro Therapeutics has signed a research collaboration with Daiichi Sankyo’s San Diego research institute to create tumor‑activated antibody‑drug conjugates (ADCs) using Voro’s PrimeBody platform. The partnership will focus on masked ADCs that employ proprietary masking domains and protease‑cleavable linkers to achieve...
Chinese researchers at Shandong University have engineered the probiotic strain Escherichia coli Nissle 1917 to synthesize and deliver the anticancer drug Romidepsin directly within breast‑tumor tissue in mice. The bacteria colonized the tumors, releasing the drug locally and achieving tumor‑inhibiting...
Some exciting news tonight just published @TheLancetInfDis our @TexasChildrens @BCM_TropMed @GWSMHS hookworm anemia vaccine is showing high levels of protective immunity in human phase 2 clinical trials, nearly 100% reduction in hookworm, a project of decades https://t.co/C23cNdsa0p
On March 18, 2026, Viva Biotech announced a strategic partnership with NVIDIA to integrate high‑performance AI computing into its drug discovery workflow through a new ‘lab‑in‑the‑loop’ platform. The collaboration will combine Viva’s proprietary biological data sets with NVIDIA’s GPU‑accelerated AI...
On March 17, 2024, the U.S. Food and Drug Administration issued a complete response letter declining approval of Aldeyra Therapeutics’ dry‑eye disease candidate reproxalap. The decision, the third regulatory setback for the drug since 2023, sent Aldeyra’s shares tumbling more...
Millions of protein complexes added to AlphaFold Database shed light on how proteins interact https://t.co/Kt9oFFkAf2 https://t.co/tEnlYOTCPl
Zymeworks reported Q4 2025 revenue of $106 million, up from $76.3 million, while net loss narrowed to $81.1 million as operating expenses fell. The company highlighted Phase III zanidatumab data showing median PFS over one year and overall survival beyond two years in first‑line...
Zymeworks will present Phase 1 data on its folate‑receptor‑alpha ADC ZW191 and preclinical results for a novel pan‑RAS inhibitor ADC platform at the AACR Annual Meeting. The oral presentation will detail dose‑escalation safety and efficacy in advanced solid tumours, while...
ORIC Pharmaceuticals announced that two preclinical abstracts on its PRC2‑targeting agent rinzimetostat (ORIC‑944) have been accepted for poster presentation at the 2026 AACR Annual Meeting. The data show rinzimetostat, an allosteric EED inhibitor, maintains potency against EZH1‑overexpressing complexes and key...
ArriVent BioPharma will showcase two preclinical posters at the 2026 AACR Annual Meeting, highlighting its EGFR inhibitor firmonertinib and the dual‑target tetravalent ADC ARR-002. Firmonertinib demonstrates high‑potency inhibition of both classical EGFR mutations and exon‑20 insertion variants, with strong brain...
Researchers at Penn State have unveiled a dual‑gate graphene field‑effect transistor that remains stable in liquid environments, eliminating the signal drift that hampers conventional sensors. By pairing a high‑capacitance top gate with a low‑capacitance bottom gate and adding a feedback...
The Drug Information Association (DIA) has launched a public‑private AI Consortium that unites regulators, biopharma, academia, and technology firms to shape AI governance in drug development. The group is developing a seven‑step classification framework that aligns AI use‑cases with risk‑proportionate...
Our bottleneck for some of the biggest change ahead may be humans. I shared the story of Paul Conyngham and his dog Rosie on my Instagram when it broke. When I read the coverage, my shock was less that ChatGPT...
A NIH‑backed multicenter trial of 140 pregnant adults found that weekly injectable extended‑release buprenorphine achieved significantly higher rates of illicit opioid abstinence than daily sublingual buprenorphine, while also reducing serious maternal adverse events. The study, published in JAMA Internal Medicine,...
Researchers at Japan’s National Agriculture and Food Research Organization engineered an anhydrobiotic Pv11 cell line to express the fruit‑fly odorant receptor Or47a and calcium‑sensitive reporter GCaMP6f. The resulting Pv11‑00443‑Or47a cells kept the insect’s extreme desiccation tolerance, enabling dry storage at...
Sanofi unveiled pre‑clinical data for an in‑vivo CAR‑T platform that delivers mRNA via lipid nanoparticles (LNPs) and a CD8‑targeting VHH nanobody, eliminating the weeks‑long ex‑vivo manufacturing step. The approach achieved tumor suppression in mice with less than 5% liver uptake...
GIP preferentially enhances glucose storage and triglyceride deposition in healthier subcutaneous fat, particularly under conditions of hyperinsulinemia and hyperglycemia. Tirzepatide contains a GIP agonist. https://doi.org/10.2337/db10-0098 https://www.gatlan.com/ @GatlanHealth
In this episode, host Volime Vesela, a physician‑scientist and CEO of Bexerg, discusses his startup’s groundbreaking work reviving dead human brains to create an intact human brain lab for drug testing. He explains how his Croatian co‑founder, Dr. Josep "Joe"...
Biotech firm Bicycle Therapeutics announced it will lay off roughly 30% of its workforce, about 86 employees, as it deprioritizes its experimental ADC zelenectide‑pevedotin. Regulators expressed doubts that the Phase 2 Duravelo‑2 trial data will support accelerated approval for metastatic bladder...
Delix Therapeutics announced the results of a Phase 1b study of zalsupindole, a selective 5‑HT2A receptor partial agonist, in patients with major depressive disorder. The trial, published in the January 2026 issue of ACS Chemical Neuroscience, demonstrated favorable safety, tolerability, and early...
A study asserts lack of disproportionate loss of muscle mass or strength cf weight loss from GLP-1 drug treatment, in mice and a small short term (12 weeks) trial in men The issue remains unsettled and counters the efforts by companies...
Scientists at Sanford Burnham Prebys and UCLA unveiled metapipeline‑DNA, a new computational tool that automates quality control, variant calling, and reporting for large‑scale genome sequencing. The pipeline processes roughly 100 GB per human genome and can scale to hundreds of samples,...
Biodegradable polymers are emerging as versatile carriers for immunotherapeutic agents, offering tunable degradation, enhanced antigen presentation, and intrinsic immunomodulatory properties. The review evaluates synthetic and natural polymers such as PLGA, PBAEs, Ace‑DEX, chitosan, alginate, and hyaluronic acid, highlighting their formulation...
Researchers introduced BQTML‑CB, an NQO1‑responsive prodrug that releases cytochalasin B inside tumor cells, disrupting actin filaments and halting migration and proliferation. The design exploits the enzyme NQO1, overexpressed in many aggressive cancers, to achieve tumor‑selective activation while sparing NQO1‑deficient cells and...
Researchers have engineered biomimetic nanocarriers that combine liposomal structures with Myxobacteria outer‑membrane vesicles (OMVs) to deliver antibiotics. The hybrid carriers achieve higher drug loading and can penetrate intracellular Gram‑negative pathogens, while native OMVs avoid immune clearance and sustain extracellular exposure....
The review highlights how bacterial membrane composition critically shapes the activity of antimicrobial peptides (AMPs) and outlines experimental and computational strategies for their rational design. By examining case studies, it maps structure‑activity relationships that govern membrane disruption versus intracellular targeting....
The review surveys nature‑inspired nanocarriers—viral vectors, extracellular vesicles, liposomes, lipid nanoparticles, and engineered membrane particles—as delivery platforms for CRISPR genome editors. It details how these systems improve editing specificity, lower immunogenicity, and surmount cellular barriers that have limited therapeutic rollout....
A new review outlines recent progress in hybrid 3D bioprinting that combines inkjet, extrusion, and vat photopolymerization to fabricate multiscale tissue constructs using sustainable, renewable biomaterials. The authors highlight how integrating multiple printing modalities overcomes single‑technique limitations, enabling nano‑ to...
Researchers have engineered recombinant suckerin‑12 colloids and hydrogels that act as wet‑resistant tissue adhesives. The materials exhibit stronger adhesion than traditional mussel‑derived proteins and outperform fibrin glue in hemostasis, cell proliferation, and wound closure in animal models. Low cytotoxicity, minimal...
The FDA issued a third complete response letter rejecting Aldeyra Therapeutics' lead dry‑eye candidate, reproxalap, citing a lack of substantial evidence and inconsistent efficacy data. The agency noted the drug failed to demonstrate clear benefit in well‑controlled studies, though no...
Bristol Myers Squibb faces a major patent cliff as flagship drugs like Revlimid, Pomalyst, Opdivo and Eliquis lose exclusivity, threatening its revenue base. To counteract the decline, the company is reshaping its pipeline through internal R&D and high‑profile acquisitions, emphasizing...
The United States faces a transplant shortage of over 100,000 patients, prompting research into xenotransplantation using genetically engineered pig organs. Recent cases—David Bennett’s pig heart in 2022, Lawrence Faucette’s in 2023, and Tim Andrews’ pig kidney in 2025—demonstrate feasibility, with...
Persistent Systems has partnered with NVIDIA to bring Agentic AI to the healthcare and life‑sciences sector, focusing on computational drug discovery. Leveraging NVIDIA’s full AI stack—including AI Enterprise, BioNeMo, the NeMo Agent Toolkit, and NIM microservices—Persistent built GenMolVS, a generative...
In February 2026 the European Commission and the CHMP granted marketing authorisations and positive opinions for a slate of innovative therapies spanning COVID‑19, oncology, cardiology, immunology and rare diseases. Notable approvals include Moderna’s mNEXSPIKE COVID‑19 vaccine, Hansoh’s Aumseqa for EGFR‑mutated...
I've always been fascinated by animals that can survive being frozen—cell walls are delicate and can be destroyed by ice crystals. HOHCells just launched FreezOpt, which is designed to keep cells intact during cryopreservation. It enables controlled initiation of ice...
Newer sepsis diagnostics such as monocyte distribution width (MDW), Intellisep, and MeMed BV are showing promise in early clinical studies but each has distinct limitations. MDW, available on the Beckman Coulter CBC platform, improves sepsis detection when combined with white‑blood‑cell...
Scientists at the University of Manchester have developed a blood test that detects brain tumours with 90% accuracy by measuring a pair of proteins. The test, validated in glioblastoma patients, is being evaluated in a multi‑site clinical trial across six...
In this DDW Highlights episode, Bruno Quinney reviews four major stories: a Mayo Clinic study linking the Parkinson's protein alpha‑synuclein to dramatically faster Alzheimer’s progression in women; a Texas A&M‑funded project testing extracellular vesicle (EV) therapy to modulate microglia and...
Scientists are accelerating development of mRNA cancer vaccines, with more than 120 clinical trials targeting melanoma, brain, breast, lung and prostate tumors. Early studies, such as personalized vaccines for glioblastoma, demonstrate rapid immune activation and improved survival. Simultaneously, a false...
In response to suggesting peptide drugs should have good evidence on safety and efficacy in order to weigh the risks and benefit…
Bicycle to lay off 30% of staff, pivot away from Padcev challenger https://t.co/m3JFu2mwoB @ByJonGardner $BCYC $PFE $MRK
Acute asthma and COPD exacerbations remain a costly, life‑threatening gap despite advances in chronic therapies. Connect Biopharma, led by Barry Quart, is the first biotech targeting these flare‑ups with a biologic that blocks IL‑4Rα, aiming to curb upstream inflammation. The...
From Prof Jin and my colleagues @scrippsresearch the largest in vivo CRISPR data engine, nearly 8 million cells, in collaboration with @nvidia and featured at GTC
Pfizer’s Ibrance successor moves forward with new study data https://t.co/ozXAZYmc3M by Kristin Jensen $PFE $LLY $NVS $RHHBY $ONC
Neurodegenerative diseases at the single-cell level, a powerful tool to differentiate and better understand https://t.co/Pkz4qW0ELM @jclinicalinvest https://t.co/LiJ4FojRYZ
Some clinical updates tell you exactly what they are. Others ask to be read twice. CytomX’s latest CRC data belong firmly in the second category. Is the die cast? https://t.co/dfdPxx4zXs https://t.co/y9QAoahMut
A great read: What we can learn from evolving proteins "A signal hidden in Mulitple Sequence Alignments (MSAs): amino acid positions that tend to co-vary in the MSA tend to interact with each other in the folded structure, often via direct...
1/ You think the biggest danger in genomics is bad data. More than that. It's the mistakes you make—without knowing. Here are the ones I learned the hard way. 🧵 https://t.co/3oj9cseVq7
